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Background: Fractures associated with bone fragility in older adults signal the potential for secondary fracture.
Fragility fractures often precipitate further decline in health and loss of mobility, with high associated costs for
patients, families, society and the healthcare system. Promptly initiating a coordinated, comprehensive
pharmacological bone health and falls prevention program post-fracture may improve osteoporosis treatment
compliance; and reduce rates of falls and secondary fractures, and associated morbidity, mortality and costs.
Methods/design: This pragmatic, controlled trial at 11 hospital sites in eight regions in Quebec, Canada, will recruit
community-dwelling patients over age 50 who have sustained a fragility fracture to an intervention coordinated
program or to standard care, according to the site. Site study coordinators will identify and recruit 1,596 participants
for each study arm. Coordinators at intervention sites will facilitate continuity of care for bone health, and arrange
fall prevention programs including physical exercise. The intervention teams include medical bone specialists,
primary care physicians, pharmacists, nurses, rehabilitation clinicians, and community program organizers.
The primary outcome of this study is the incidence of secondary fragility fractures within an 18-month follow-up
period. Secondary outcomes include initiation and compliance with bone health medication; time to first fall and
number of clinically significant falls; fall-related hospitalization and mortality; physical activity; quality of life; fragility
fracture-related costs; admission to a long term care facility; participants’ perceptions of care integration,
expectations and satisfaction with the program; and participants’ compliance with the fall prevention program.
Finally, professionals at intervention sites will participate in focus groups to identify barriers and facilitating factors
for the integrated fragility fracture prevention program.
This integrated program will facilitate knowledge translation and dissemination via the following: involvement of
various collaborators during the development and set-up of the integrated program; distribution of pamphlets
about osteoporosis and fall prevention strategies to primary care physicians in the intervention group and patients
in the control group; participation in evaluation activities; and eventual dissemination of study results.
Study/trial registration: Clinical Trial.Gov NCT01745068
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Among Canadians over 50 years of age, close to two in
five women and one in six men will experience at least
one fracture due to bone fragility (FF) [1-3], in other
words a fracture resulting from minimal trauma or a fall
that would not harm a healthy person. In women over age
50, the annual FF incidence rate is 14/1000, twice the inci-
dence rate of cerebrovascular incidents and myocardial
infarcts combined [4]. FFs cost Canada’s healthcare ser-
vices over $2 billion annually [5,6], with costs expected to
triple over the next 20 years [7,8].
Recent statistics reveal that about two million Canadians
suffered from osteoporosis defined by bone mineral
density (BMD) [9], but BMD is an imperfect measure of
bone strength. Although FFs are generally related to bone
fragility related to osteoporosis [1,10-13], and the relative
risk for FF increases with decreasing BMD, the majority of
FFs occur in individuals without BMD-defined osteo-
porosis. The occurrence of a FF is a sentinel event pre-
dicting a future FF [14], at least doubling the risk of
secondary fractures compared with age- and BMD-
matched individuals without a FF [15,16]. Indeed, men
and women with a hip or spine FF are at high risk for
repeat fractures, irrespective of their BMD results, which
may be normal. Of note, about half of hip fracture pa-
tients have sustained previous FFs [17,18], suggesting
that FFs are events that should guide preventive inter-
ventions. Hip fractures often precipitate decline in health
or even death, and loss of mobility, with high associ-
ated costs for patients, families, society and the healthcare
system [19-23].
The two mainstays of FF prevention are pharmaceut-
ical interventions to strengthen bones, and fall preven-
tion programs to maintain and improve strength and
balance, including other strategies to reduce fall risk fac-
tors, keeping in mind that exercise also strengthens
bones. The success of interventions to manage FFs more
effectively, to identify and treat those with bone fragility,
to maximize population health by preventing or delaying
frailty, and to minimize costs [24-28] is mediated by
the context of interventions within the local healthcare
system [29,30]. Despite strong evidence of their effective-
ness, prescription and adherence to osteoporosis treat-
ment and fall prevention interventions following FFs
remain sporadic and inconsistent in primary care. It is
hoped that when post-fracture screening and fall preven-
tion programs are systematically integrated, and secondaryFFs may be prevented in an additive or even synergistic
manner [30,31].
In the context of current primary care reform, second-
ary fracture prevention program research must evaluate
multidisciplinary and interorganizational strategies, with
attention to the regional context of implementation, the
providers, and the participants. The present paper in-
cludes the design and evaluation procedures for a novel
secondary FF prevention program, involving collaboration
between secondary healthcare practitioners (orthopedic
surgeons and medical bone specialists), primary care
physicians (PCPs), group practice nurses, and local and
provincial fall prevention programs, being implemented in
the province of Quebec, Canada. This work builds on the
Osteoporosis and Peripheral fractures: Treatment and
Investigation through Multidisciplinary care at the CHUS
(OPTIMUS) intervention. The proposed intervention in-
volves PCPs in the evaluation and treatment of osteopo-
rosis following FFs treated by orthopedic surgeons [32-38]
and integrates local and provincial fall prevention pro-
grams implemented in the province of Quebec, including
the Personalized Multifactorial Intervention (PMI), an
individualized program offered to the most frail elders
considered at risk for falls [39]; and a community-based
fall prevention program aimed primarily at improving
balance and strength through exercise for elders who have
fallen or are concerned with falls (Stand Up!) [40]. This
integrated program will be orchestrated by site study
coordinators.
The overarching aim is to investigate the effectiveness,
cost-effectiveness and cost-utility of an integrated FF
prevention program, and to obtain a portrait of the bar-
riers and facilitating factors for such programs. More
specifically, the objectives are:
1. to combine existing fall prevention and post-fracture
management programs in the province of Quebec into
integrated interdisciplinary FF prevention programs;
2. to compare the performance of these integrated
programs to results from control sites, using a
pragmatic study design;
3. to identify barriers as well as factors that improve
effectiveness across different implementation regions;
4. and to develop and engage in active knowledge
transfer activities in Quebec regions where integrated
FF prevention programs are neither adequately nor
successfully implemented.
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Primary question
Can an integrated FF program reduce the risk of a second-
ary FF in a population of patients 50 years of age and over,
who sustained a FF 18 to 20 months previously?
Secondary questions
1) Can a post-FF management program be successfully
integrated with PCPs’ health care, and local and
national fall prevention programs, from a patient and
healthcare system perspective?
2) Is this integrated FF prevention program effective
and cost-effective?
3)What are the barriers and factors that improve
effectiveness across different implementation
regions?
Drawing upon the literature on integrated healthcare,
fall and fracture prevention, as well as the OPTIMUS
study [32-38], we hypothesize that an integrated FF pro-
gram can reduce the risk of a secondary fracture by at
least 30% in the population of interest. In addition, by
examining the implementation process of the program,
we will make recommendations to circumvent the bar-
riers to implementation, and to build upon the factors
that lead to improved integration of the care providers
involved in the program.
Conceptual framework
The research program will draw on the key principles of
the Development Model for Integrated Care (DMIC)
[41-43] to implement the proposed intervention, and the
Model of Structuration of Interprofessional Collaboration
(MSIC) to explore interorganizational collaboration and
its links to the selected clinical outcomes [44].
The DMIC is a recent model for the development of
an integrated program [41-43] that has been validated
through a panel of Dutch experts and is currently imple-
mented within three settings in The Netherlands. This
project will tap into the first and second phases of the
DMIC model: Initiative and design; and Experiment and
execution. These serve as a checklist for the develop-
ment of the program in each intervention region, and
as a guideline during the focus group discussions with
the participating healthcare professionals involved in the
intervention.
The MSIC lists 10 indicators, grouped into four dimen-
sions: Shared goals and vision; Internalization; Formal-
ization; and Governance. These indicators capture facets
of relationships between individuals engaged in a collab-
orative practice, and the organizational context in which
they work [44]. The MSIC has been validated in various
healthcare contexts, mostly in the province of Quebec[45-47]. It will be used to guide the evaluation of collabo-
ration among practitioners and organizations involved in
the program (hospitals, orthopedists and medical bone
specialists, PCPs in private practices, family medicine
group (GMFs), and provincial and local fall prevention
services).
Methods
Study design
A pragmatic, controlled trial design is being used to as-
sess whether the intervention works in a setting that is
as similar to routine practice as possible [48]. Within
such a design, all participants are enrolled unless the
study intervention might compromise patient safety;
treating physicians and healthcare practitioners decide
how the intervention is delivered; integrated models of
healthcare are encouraged, as the intervention is deliv-
ered through the participation of a spectrum of practi-
tioners in a range of healthcare organizations; and an
intent-to-treat analysis is the only analysis possible [48-52].
Setting
The study is taking place in eleven hospitals and various
fall prevention programs, located in eight different admin-
istrative regions of the province of Quebec. Of these, six
hospitals are offering the integrated program in four dif-
ferent regions (Sherbrooke, Lanaudière, and Montréal),
while participants recruited from the other five hospitals
(in the Outaouais, Trois-Rivières, Longueuil, Côte-Nord,
and Amos regions) will constitute the standard care con-
trol group. The choice of these hospitals and regions is
based on the variety of fall prevention programs available
in the geographic area surrounding the selected hospitals
[53]. The broad variety of sites will maximize the external
generalizability of the study results, and is intended to
optimize the potential identification of barriers to and fa-
cilitating factors for implementation of an integrated FF
prevention program.
Ethical approval
Given the large number of organizations involved, ethical
aspects of this study were evaluated via a multi-center
mechanism as recommended by the Ministère de la Santé
et des Services Sociaux (MSSS). The Comité d’éthique de
la recherche en santé chez l’humain du Centre hospitalier
universitaire de Sherbrooke (CHUS) served as the princi-
pal ethics board and approved the final documents.
Participants
The study population consists of community-dwelling
males and females, who are 50 years of age and over, who
have a PCP (this is the case for 94% of this age group in
Canada [54]), who are able to follow simple instructions,
and who have sustained a FF within two months of the
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ing conditions will be excluded: fracture at sites not com-
monly associated with osteoporosis such as toe, finger,
hand, foot, patella, head, and cervical spine; severe kidney
insufficiency (grade 4 or 5); or an advanced stage of cancer
or any other disease from which the patient is likely to die
within the next year.
Recruitment
Drawing upon the methodology of previous studies in a
similar population [32-34,55], participants for interven-
tion sites will be recruited by a study coordinator over a
period of 12 months, and will provide their informed
consent to participate and complete the baseline ques-
tionnaire. Three methods will be used to recruit inter-
vention group participants:
1. Patients with FFs in participating outpatient orthopedic
clinics will be identified by a study coordinator;
2. Hip fracture inpatients will be approached on the
ward during their hospitalization;
3. And hospital emergency and ward discharge
administrative data will be scanned for patients with
a primary discharge code typical of a FF. These
participants will be contacted by mail by the hospital
to inform them about the research project and that a
local study coordinator will contact them. Electronic
discharge data allows patient identification within
one week following discharge.
Due to budgetary and ethical considerations, only
strategy 3 will be used to recruit participants in the con-
trol hospitals/regions. Should it be required as an alter-
native, FF patients’ identification through the Régie de
l’assurance maladie du Québec (RAMQ) database will be
considered, as in the Recognizing Osteoporosis and its
Consequences in Quebec (ROCQ) study [55]. The main
limitations of this alternative strategy as well as strategy
3 are a delay required to obtain patients’ information
(estimated at two months in the case of the RAMQ data,
one week for the hospital administrative data), and a po-
tential selection bias (those more at risk for fractures, or
who are younger and more educated may be more likely
to consent); however, such strategies might be an effi-
cient way to increase the external validity of the study by
recruiting a broader range of fracture patients.
Study interventions
Intervention group
Nurses working in the Family Medicine Groups and
Cliniques-Réseau (in Montreal) (GMF/CRs) located in
the areas served by the recruiting hospitals will receive a
workshop on evidence-based pharmacological interven-
tions for osteoporosis, and benefits of exercise and fallprevention strategies to prevent FF. All PCPs within the
intervention group regions will receive a pamphlet sum-
marizing the workshop.
Upon recruitment, FF participants will be educated by
the study coordinator about osteoporosis as the cause of
their FF, the importance of a rapid screening evaluation for
potentially treatable primary causes of bone fragility, the
benefits of early and prolonged treatment, the options for
treatment to be adapted for individuals, and will be asked
permission to contact their PCP and community pharma-
cist. Participants’ PCPs will receive written information
containing a presumed osteoporosis diagnosis, investiga-
tions to be performed, correct interpretation of bone
densitometry results in the context of a FF, treatment
options adapted to the individual patient, and alternatives
if the first prescriptions are not tolerated or are stopped.
The integrated intervention per se includes the following:
1. When possible, screening basic blood tests (e.g.,
calcium, phosphate, white blood cells, hemoglobin,
platelets, vitamin D) in the context of a FF will be
performed at the recruiting hospital laboratory, and
the results will be transmitted to the participant’s
PCP with a personal letter explaining the importance
of seeing the patient rapidly (ideally within one
month), and the urgency of initiating an osteoporosis
treatment. If the PCP is part of a GMF/CR [56], then
the clinic nurse will receive a copy of the information
sent to the PCP.
2. Following a region-specific a priori defined algorithm
to identify the most relevant resource for the
participant, the study coordinator or the GMF/CR
nurse (when possible) will orient the participant to
an appropriate fall prevention program, and organize
his/her registration or placement on the waiting list.
A local exercise and fall prevention program
appropriate for the patient according to the
participant’s age, fracture risk, and abilities will be
agreed upon by the study coordinator and the
participant. The study coordinator will work with
numerous local fall prevention champions supporting
this research program, to establish and maintain an
up-to-date list of available exercise and fall
prevention programs at each site. The study
coordinator will also encourage the participant to
engage in additional physical activities at a
comfortable level of intensity.
3. The participant will be called quarterly by the study
coordinator or the GMF/CR nurse to monitor
pharmacological treatment adherence, to detect and
correct (if appropriate) inadequate intake or side
effects affecting compliance, to answer questions, to
encourage compliance, and to track fall and fracture
information recorded in the participant diary.
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communicate with the participant’s pharmacist at 6
and 12 months to confirm drug delivery to the
participant (if the participant has been prescribed
osteoporosis pharmacological treatment), and if
possible to enlist this professional’s help in
encouraging treatment.
5. At each follow-up, if the patient is not taking an
adequate pharmacological treatment, a letter will
be sent again to the PCP (and the GMF/CR nurse,
if appropriate) suggesting that they treat the
patient according to the participant’s 10-year
fracture risk.
6. Participant adherence to the fall prevention program
will be monitored at the mid-point and at the end of
the program. If necessary, the study coordinator will
arrange a program change to better fit the
participant’s needs.
Control group
The study coordinator will inform the participants about
osteoporosis as the potential cause of their fracture. A
lay pamphlet on strategies to prevent a secondary FF will
be provided, including the recommendation to visit their
PCPs and the need for fall prevention and pharmaco-
logical intervention in most patients.
Outcomes and data collection
All participants will be followed for a period of 18 months.
A multilevel approach is being used, in which outcomes
at the patient level will be measured with quantitative
tools, and outcomes at the organization level (e.g., per-
ception of the degree of integration and collaboration
between organizations) will be measured simultaneously
using qualitative techniques [57]. Combining both qual-
itative and quantitative measures will allow a better
understanding and contextualisation of the quantitative
results, and verification as to how organization level
factors impact the effectiveness outcomes [57,58].
Quantitative data
With the exception of the first encounter with the parti-
cipants recruited from the orthopedic clinics and the
inpatients from the intervention sites with hip and other
fractures, all data will be collected through phone
surveys and the participant diary. A baseline question-
naire will be completed by all participants, including
demographic data and relevant medical history (e.g.,
height, weight, smoking and drinking history, family
history of hip fracture, use of glucocorticoids) and the
CaMos questionnaire [59]. The Fracture Risk Assessment
Tool (FRAX) score will be used, irrespective of BMD
results availability [60]. A Canadian Association of Radiol-
ogists and Osteoporosis Canada 10-year absolute fracturerisk (CAROC) score will be generated for participants
who undergo a BMD test within +/− 3 months of the sen-
tinel event [59,61]. A study exit questionnaire will be
administered at the end of the intervention or when the
participant withdraws his/her consent to participate.
Primary outcome
The primary outcome is the incidence of secondary FF
during the 18-month follow-up period, including the
date of the event, related emergency room visit, and
hospitalization. This will be ascertained during quarterly
telephone surveys, and confirmed with the participant’s
hospital record when possible.
Secondary outcomes
Secondary outcomes will be assessed at 3, 6, 9, 12 and
18 months unless otherwise mentioned.
1. Initiation of osteoporosis treatment by the PCP
(bisphosphonates or other effective osteoporosis
drugs) [31], and compliance with osteoporosis
treatment will be captured during telephone
surveys. The data will be validated with the
participant’s pharmacist via the medication
possession ratio, which is measured from the first to
the last prescription, with the denominator being
the duration from index to the exhaustion of the
last prescription and the numerator being the days
supplied over that period from first to last
prescription and the numerator being the total
number of days in the interval [62].
2. Time to first fall, and number of clinically
significant falls will be reported by participants from
their diary of fall events, during telephone follow-
up. This prospective method has been found to be
reliable, minimizing recall bias, in other fall
prevention studies [63].
3. Fall-related hospitalizations will be recorded in the
participant diary and at each telephone follow-up,
and validated with the participant’s hospital records.
4. FF-related death will be confirmed from the RAMQ
administrative database.
5. Participants’ quality of life will be documented bi-
annually during telephone surveys, using the EQ-
5D-3 L questionnaire [64]. This is an extensively
validated questionnaire that provides a global
measure of the respondent’s health status and
quality of life [65-67].
6. Practice of physical activities will be measured
using the Community Healthy Activities Model
Program for Seniors (CHAMPS) [68,69]. This tool
has demonstrated very good psychometric
properties and sensitivity, even with low intensity
physical activities.
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duration. Medical costs from the participant’s
hospital record include: medical assessment,
prescription and non-prescription drugs; and
resource use related to the management of the FF
and/or long-term complications, including
hospitalization. Also, lost days of work, annual
income (if the participant is in the labor force),
travel to the hospital and/or rehabilitation facilities,
parking, and out-of-pocket expenses for drugs and
rehabilitation devices (e.g., splint) will be compiled.
Protocol-driven costs will be excluded, with the
exception of the costs related to the participant’s fall
prevention program.
8. Admission to a long-term care facility will be
queried during each telephone survey.
9. All participants’ perceptions of care integration will
be captured in the exit questionnaire. In the
absence of a formally validated instrument to
measure the outcome of interest [70], the
measurement tool will consist of a customized
version of a questionnaire on the perception of care
integration from a patient perspective [71]. Five
questions, corresponding to the interaction
subscale, are being used to investigate this study
objective on program integration.
10. Intervention participant’s satisfaction with the FF
prevention program will be measured using
questions similar to those used by Berendsen et al.
for their assessment of the sources and amount of
information preferred by the participant in the
context of an integrated program [72], along with
general questions with regards to the participant’s
satisfaction with the program.
11. Participants’ expectations and whether they are
perceived as met will be collected at the beginning
and end of the program. The questionnaire is an
adapted version of Gignac’s Program Expectation
Scale and uses a 3-point scale ranging from 1 (not
at all likely) to 3 (extremely likely) [73]. Participants
will also be asked to rate the extent to which they
believe the program would produce (before the
program) or has produced (end of the program)
health benefits for themselves.
12. Individuals who chose to leave the program (or part
of it) will be contacted by telephone to document
the reason(s) for withdrawing while completing the
exit questionnaire.
Qualitative data
Focus group sessions organized per intervention region
will gather a purposeful sample of healthcare managers
of fall prevention programs, medical bone specialists,
orthopedic surgeons, PCPs and GMF nurses involved inthe trial, as well as patients. The sessions are scheduled
to last about 60 minutes in length. A maximum of eight
professionals will participate per focus group, so sessions
with healthcare professionals will be repeated twice for
greater participation. The topics and questions of the
semi-structured questionnaire will be guided by the con-
ceptual frameworks selected for this project [41,44]. The
first session (at baseline) will aim to understand both
the factors for success and the potential barriers to the
implementation of a FF prevention program. The second
session will target the barriers and facilitating factors for
maintenance of a FF prevention program, as well as
measure the degree of integration between the organiza-
tions involved (at 12 months). The two focus groups for
the patients (one at baseline and another one between
12 and 18 months post-recruitment) will be geared to-
wards patients’ expectations and satisfaction about the
program, as well as perception of integration of care. All
focus group sessions will be audiotaped and transcribed.
Statistical analysis
Sample size
Quantitative evaluation of entire cohort Based on pre-
liminary (almost four years follow-up) results from the
OPTIMUS project, the incidence of a secondary fracture
at 16 months in the control group is expected to be
10%; therefore, this incidence of fracture was used as a
proxy for the sample size calculation of this project (pri-
mary outcome measured at 18 months). Considering the
reported efficacy of antiresorptive drugs among others
(average absolute reduction rate of 4%) [74-77], the results
obtained in the intervention group of the OPTIMUS
cohort (expected absolute reduction rate in FF of 2.5%),
as well as the expected synergy with fall prevention pro-
grams, and collective orders that will allow for a rapid
pharmacological intervention, an absolute reduction of
3% (i.e., a secondary fracture incidence at 18 months of
7% in the intervention group) is a conservative estimate
of the effect to be detected. Under these assumptions and
assuming a power of 80% and an alpha level of 5%, 1,356
participants per group are necessary to verify the primary
hypothesis. It is estimated that approximately 15% of the
participants will be lost to follow-up or will withdraw from
the study prior to the 18-month data collection time
point. Therefore, a total of 1,596 participants will be
recruited in each group (total N = 3,192).
Qualitative focus group analyses Based on the qualita-
tive literature, it is estimated that 6 to 12 participants
are required to achieve study themes redundancy
[78,79]. Our targeted sample size should then allow for
the saturation of the various barriers to and facilitators
of the implementation of an integrated FF prevention
program (first sessions’ focus), as well as the qualitative
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oration within each intervention site (second sessions’
focus) [80,81].
Data analysis
Quantitative component
Descriptive summaries of baseline participant character-
istics in the control and intervention groups will be gen-
erated. Any statistical differences (due to selection bias,
for example) between the study groups or within a study
group (between the different sites) will be tested using
chi-square tests or Student’s t-tests (or their non-
parametric equivalents if necessary) and accounted for
in the following analyses. According to the pragmatic
design standards, statistical analysis of the data will fol-
low the intention-to-treat principle; i.e., the analysis will
include all patients regardless of their compliance with
their study group intervention. The implementation
process will also be documented with descriptive statistics.
Primary outcome
The numbers of participants presenting with a least one
secondary FF at 18 months will be compared using a
chi-square test. A logistic regression model will be fit to
assess the intervention effect, while adjusting for vari-
ables thought to influence the outcome and accommo-
dating any imbalance between groups at baseline. The
intervention effect and its 95% confidence interval will be
generated. Descriptive statistics on the cumulative inci-
dence of recurrent FF will also be generated for each group.
Secondary outcomes
Initiation and compliance with pharmacological osteo-
porosis treatment at 3, 6, 9, 12 and 18 months, and mor-
tality rate will be analysed independently, as for the
primary outcome. Time to first fall will be compared be-
tween study groups using a time-to-event type of ana-
lysis (log-rank test or Gehan-Wilcoxon, depending on
the data distribution). A Cox regression model that
allows for the adjustment of baseline variables that have
been shown to influence the outcome will be used. The
difference in the number of significant falls and fall-
related hospitalizations will be assessed using a Poisson
regression model. Participants’ quality of life and prac-
tice of physical activities measured over time will be fit
and compared between the two study groups using an
analysis of variance (ANOVA) for repeated measures.
The total score of the participant’s perception of care in-
tegration will be generated for each participant by sum-
ming up all questionnaire items. Group scores will be
compared using a linear regression model. If numbers
allow, a sub-group analysis will be considered among the
intervention group to test the effect of provincial versuslocal fall prevention programs as a covariate on the pri-
mary outcome.
The cost-effectiveness ratio will be expressed as the
difference in costs between the study groups, divided by
the difference in secondary fracture rates between the
two groups. Costs will be calculated as the units of
resources used in the treatment of a FF, multiplied by
the cost of one unit. The uncertainty concerning the in-
cremental cost, the incremental effectiveness, and the in-
cremental cost-effectiveness ratio will be estimated by
conducting probabilistic analysis through non-parametric
bootstrapping [82]. Results from the bootstrapping exer-
cise will be depicted by cost-effectiveness acceptability
curves. All quantitative analyses will be performed with
the SPSS 18 software (SPSS, Inc., 2009, Chicago, IL), with
the exception of the economic analyses, which will be per-
formed using Oracle Crystal Ball (http://www.oracle.com/
us/products/applications/crystalball/index.html).
Qualitative component
Focus group audio tapes and transcripts will be reviewed
simultaneously to assess validity of the transcription
process. An interpretive approach will inform the ana-
lysis of the transcript [83,84]. Two examiners will read
the transcripts independently, and a thematic analysis
will be conducted to identify themes that emerge, that
correspond to the study questions. Codes will be com-
pared and discussed until an acceptable inter-judge reli-
ability is obtained [83]. Data analysis will be conducted
using the scoring scheme proposed by D’Amour and col-
leagues [44,85], and supported by the NVivo software.
An audit trail will be compiled to record the steps taken
and decisions made during the analytical process, which
will ensure the reproducibility of the analysis. Data sat-
uration will be considered to have been reached when a
theme has been discussed by at least six interviewees
[78]. Analysis will examine coherence and differences
among the focus group participants, and will be dis-
cussed within a small subgroup of the research team. In-
tegration with the quantitative data will be considered,
especially for explanation of any foreseen variation in
the primary outcome between the intervention sites.
Knowledge translation and dissemination
Several activities will serve to meet the fourth objective
of this project related to knowledge translation through-
out the intervention [86]:
1. A panel of volunteer healthcare professionals
involved in the treatment of FF and public health, as
well as a patient representative from the intervention
regions, will design the pamphlets for the control
participants, and for the intervention PCPs.
Webminars will also be offered to healthcare
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done through a modified Delphi survey [87-89] with
refinement using a focus group including a
maximum of 12 participants. This initiative will
create expectations among the professionals and
their communities, while sensitizing them to the
clinical and economic burden of FFs. This strategy
will also empower these professionals vis-à-vis the
research team, thus creating a fertile environment for
active collaboration and knowledge transfer during
the trial.
2. The personalized letter sent to the intervention
group participants’ PCPs is an excellent opportunity
for knowledge transfer and continued education.
When carefully designed, this mode of
communication between secondary and primary care
has shown benefits, especially with the older adult
population [90-92].
3. A final report as well as an information session will
be prepared for the MSSS and the Institut national
de santé publique du Québec (INSPQ) decision
makers and managers to inform them about the
study results and to promote the sustainability and
expanded geographical coverage of the program.
4. We anticipate that the process of evaluation of the
currently available fall prevention programs will
affect the willingness of managers to pursue
evaluation of the organization (e.g., hospitals, medical
group practices, provincial and local fall prevention
programs) and delivery processes of their programs.
Such a bottom-up approach might eventually
improve the knowledge translation and dissemination
of the proposed study recommendations with the
confidence that these will have a longer and
measurable impact upon the organizations involved.
Moreover, the involvement of collaborators
committed throughout major networks of action
among the government and osteoporosis knowledge
transfer groups should facilitate the translation of the
results among the population and stimulate the
creation of other similar initiatives in the province.
5. Conventional knowledge translation strategies such
as presentations to national and international
conferences and publications in peer-reviewed open-
access journals will also be undertaken.
Discussion
This trial is testing a comprehensive, integrated second-
ary FF prevention program in a real-life setting, and is
designed to optimize translation of research evidence
into practice [93-95]. The pragmatic evaluative design of
this project, rooted in the Canadian Institutes of Health
Research Integrated Knowledge Translation process [96],
will provide estimates of the effectiveness of a FFprevention program in different socioeconomic contexts,
thereby increasing the generalizability of the results.
FF prevention is needed for much longer time periods
than the length of this study, and the creation of a cohort
of patients who have experienced FFs offers an opportu-
nity to further address continuity and gaps regarding inte-
grated FF prevention programs. The study team is seeking
funding for continuing research, including follow-up at
five years.
A limitation of this study lies in the recruitment strat-
egies. Patients in the control group, identified through
administrative databases, may present with more severe
risk factors, which translate into a higher likelihood of a
secondary FF. This may create a selection bias between
the recruiting sites, which will be accounted for in the
statistical analyses. In the intervention group, a surveil-
lance bias for secondary FF is possible, since this group
is sensitized to FFs. This may reduce the observed study
effect; however, the large size of this trial, based on con-
servative effect estimates, should provide sufficient power
to detect the intervention effect, if present. Finally, control
sites/regions will be monitored throughout the trial to
identify emerging fall prevention programs. This will be
accounted for in the statistical analysis should participants
take part in these programs. Another limitation related to
the external validity of this study lies in the organizational
variations between participating regions. However, the
qualitative component of the study should shed light on
those variations and help in a more accurate interpre-
tation of the results.
The number of aging baby boomers, increasing lon-
gevity, and higher standards for quality of care are com-
bining to create the ‘perfect storm’ of healthcare issues
that will emerge over the coming decades. Rapidly in-
creasing numbers of FFs are a significant concern for
older adults, and place enormous demands on already
stretched health resources. Solutions to slow this ‘epi-
demic’ have already been developed and tested in prac-
tice: falls can be prevented through existing programs;
cost-effective drugs decrease the risk for fractures in high-
risk groups; and care following FFs is improving. Never-
theless, the impact of these interventions is blunted by low
patient participation and poor intervention integration.
This novel integrated FF prevention program aims to im-
prove interorganizational collaboration and communication
between both primary and secondary healthcare practi-
tioners. As we help health professionals to improve the con-
tinuum of care and patient-centered care, the goal is also to
improve chronic disease prevention and management.
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